Withdrawals due to adverse events · active EoE patients
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Procedure‐related adverse events within 3 months · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in procedure‐related adverse events within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Adverse events (1 to 6 months post intervention) · women with perinatal depression
1 finding from 1 review
Adverse events ‐ pneumonia · adults in the ICU, requiring respiratory support
It is very uncertain whether HFNC changes adverse events Respiratory infection (pneumonia) compared with NIPPV or NIV (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with severe delirium
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes adverse events including extrapyramidal effectsd compared with placebo plus haloperidol (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with chlorpromazine (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with lorazepam (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in adverse events including extrapyramidal effectse compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · hyperuricaemia in people with hypertension
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
1 finding from 1 review
Adverse effects (fall down) · adults with dementia following hip fracture surgery
It is very uncertain whether interdisciplinary enhanced rehabilitation (inpatient and community… changes adverse events (incidence of falls at 12 months) compared with conventional rehabilitation (very low certainty).
1 finding from 1 review
Adverse events (delirium during hospitalisation) · adults with dementia following hip fracture surgery
It is very uncertain whether geriatrician‐led inpatient management changes adverse events (delirium during hospitalisation) compared with orthopaedic‐led inpatient management (very low certainty).
1 finding from 1 review
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (randomisation to post‐treatment) · children and adolescents with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found